Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

NCT00568594 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00568594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
Lead sponsor
Novartis
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2007
Completion date
Not reported
Enrollment
176 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease